Key points from article :
Gero, a GenAI biotech firm, has raised $6 million to fuel its mission of tackling ageing and age-related diseases.
The company employs cutting-edge AI tools to analyse real-world health data, aiming to decode the ageing process and develop novel therapies.
Gero's physics-guided machine learning frameworks enable target discovery for chronic age-related diseases directly from human data.
Their large health models (LHMs) provide both predictions and explanations, accelerating drug discovery and ensuring accuracy.
Gero is collaborating with Pfizer and other pharmaceutical companies to revolutionise genetics-driven drug discovery.
The company envisions a future where ageing is not inevitable but a treatable condition, aiming to double human health-span and lifespan.
